Dextran-coated iron oxide nanoparticle for delivery of miR-29a to breast cancer cell line

Pharm Dev Technol. 2019 Oct;24(8):1032-1037. doi: 10.1080/10837450.2019.1623252. Epub 2019 Jun 21.

Abstract

In the last years, miRNAs have been associated with molecular pathways of cancer and other diseases. The change of expression level of miRNA has an inhibitory role in tumorigenesis. Nevertheless, the poor bioavailability of miRNA due to the rapid enzymatic degradation is a critical handicap in cancer therapy. In this study, we designed dextran-coated iron oxide-based nanoparticle for the delivery of miR-29a to breast cancer cells and analyzed its therapeutic efficacy in vitro. Results indicated that the presence of dextran-coated magnetic nanoparticles, loaded with miR29a, enhanced the selective delivery of miR-29a. Further, miR-29a complex nanoparticles caused down-regulation of anti-apoptotic genes. These results pave the way for further investigations into the possible use of miR-29a complex magnetic nanoparticles for breast cancer therapy.

Keywords: MiR-29a; apoptosis; breast cancer; dextran; nanoparticles.

MeSH terms

  • Apoptosis / drug effects
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Dextrans / chemistry*
  • Down-Regulation / drug effects
  • Female
  • Ferric Compounds / chemistry*
  • Humans
  • MCF-7 Cells
  • MicroRNAs / administration & dosage*
  • MicroRNAs / chemistry*
  • Nanoparticles / chemistry*

Substances

  • Dextrans
  • Ferric Compounds
  • MIRN29a microRNA, human
  • MicroRNAs
  • ferric oxide